Meeting
2013 Gastrointestinal Cancers Symposium
Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
Authors
Bert O'Neil
University of North Carolina at Chapel Hill
Bert O'Neil , Johanna Bendell , Manuel Modiano , Jean-Pascal Machiels , Melissa Versola , Jeff Hodge , Karen Sawarna , Nielson Tse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01271504
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr294)
DOI
10.1200/jco.2013.31.4_suppl.294
Abstract #
294
Poster Bd #
C42
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
First Author: Changhoon Yoo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2019 Gastrointestinal Cancers Symposium
Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
First Author: Emilie Wang
Poster
2017 Gastrointestinal Cancers Symposium
Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
First Author: Robin Kate Kelley